Top

Discover Oncology

Published in:

Open Access 01-12-2023 | Biomarkers | Research

BLCA prognostic model creation and validation based on immune gene-metabolic gene combination

Authors: Shao-Yu Yue, Di Niu, Xian-Hong Liu, Wei-Yi Li, Ke Ding, Hong-Ye Fang, Xin-Dong Wu, Chun Li, Yu Guan, He-Xi Du

Published in: Discover Oncology | Issue 1/2023

Abstract

Background

Bladder cancer (BLCA) is a prevalent urinary system malignancy. Understanding the interplay of immunological and metabolic genes in BLCA is crucial for prognosis and treatment.

Methods

Immune/metabolism genes were extracted, their expression profiles analyzed. NMF clustering found prognostic genes. Immunocyte infiltration and tumor microenvironment were examined. Risk prognostic signature using Cox/LASSO methods was developed. Immunological Microenvironment and functional enrichment analysis explored. Immunotherapy response and somatic mutations evaluated. RT-qPCR validated gene expression.

Results

We investigated these genes in 614 BLCA samples, identifying relevant prognostic genes. We developed a predictive feature and signature comprising 7 genes (POLE2, AHNAK, SHMT2, NR2F1, TFRC, OAS1, CHKB). This immune and metabolism-related gene (IMRG) signature showed superior predictive performance across multiple datasets and was independent of clinical indicators. Immunotherapy response and immune cell infiltration correlated with the risk score. Functional enrichment analysis revealed distinct biological pathways between low- and high-risk groups. The signature demonstrated higher prediction accuracy than other signatures. qRT-PCR confirmed differential gene expression and immunotherapy response.

Conclusions

The model in our work is a novel assessment tool to measure immunotherapy’s effectiveness and anticipate BLCA patients’ prognosis, offering new avenues for immunological biomarkers and targeted treatments.

Available only for authorised users

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen W. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135:584–90.PubMedPubMedCentralCrossRef

Xiang Z, Ye Z, Ma J, Lin Y, Zhou Y. Temporal Trends and projections of bladder cancer burden in China from 1990 to 2030: findings from the global burden of disease study. Clin Epidemiol. 2022;14:1305–15.PubMedPubMedCentralCrossRef

Bjerregaard BK, Raaschou-Nielsen O, Sørensen M, Frederiksen K, Christensen J, Tjønneland A, Overvad K, Chapelon FC, Nagel G, Chang-Claude J, Bergmann MM, Boeing H, Trichopoulos D, Trichopoulou A, Oikonomou E, Berrino F, Palli D, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Kiemeney L, Gram IT, Braaten T, Lund E, Gonzalez CA, Berglund G, Allen N, Roddam A, Bingham S, Riboli E. Tobacco smoke and bladder cancer—in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2006;119:2412–6.PubMedCrossRef

Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract. 2002;10:311–22.PubMedCrossRef

Alkhateeb A, Atikukke G, Porter L, Fifield B-A, Cavallo-Medved D, Facca J, El-Gohary Y, Zhang T, Hamzeh O, Rueda L, Kanjeekal SM. Comprehensive targeted gene profiling to determine the genomic signature likely to drive progression of high-grade nonmuscle invasive bladder cancer to muscle invasive bladder cancer. J Clin Oncol. 2020;38:568–568.CrossRef

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, Rouanne M, Thalmann GN, Veskimäe E, Ribal MJ, van der Heijden AG. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82–104.PubMedCrossRef

Song Q, Zhou R, Shu F, Fu W. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer. Front Immunol. 2022;13:958368.PubMedPubMedCentralCrossRef

Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021;11:3089–108.PubMedPubMedCentralCrossRef

Chi M, Liu J, Mei C, Shi Y, Liu N, Jiang X, Liu C, Xue N, Hong H, Xie J, Sun X, Yin B, Meng X, Wang B. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer. J Exp Clin Cancer Res. 2022;41:175.PubMedPubMedCentralCrossRef

10.

Martin A, Woolbright BL, Umar S, Ingersoll MA, Taylor JA 3rd. Bladder cancer, inflammageing and microbiomes. Nat Rev Urol. 2022;19:495–509.PubMedCrossRef

11.

Yang R, Zhang W, Shang X, Chen H, Mu X, Zhang Y, Zheng Q, Wang X, Liu Y. Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer. Front Pharmacol. 2022;13:1013672.PubMedPubMedCentralCrossRef

12.

Zheng Z, Mao S, Zhang W, Liu J, Li C, Wang R, Yao X. Dysregulation of the immune microenvironment contributes to malignant progression and has prognostic value in bladder cancer. Front Oncol. 2020;10:542492.PubMedPubMedCentralCrossRef

13.

Luo WJ, Tian X, Xu WH, Qu YY, Zhu WK, Wu J, Ma CG, Zhang HL, Ye DW, Zhu YP. Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer. J Cell Mol Med. 2021;25:4326–39.PubMedPubMedCentralCrossRef

14.

Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y, Li W, Han B, Chen S, Shi B. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82:114–29.PubMedCrossRef

15.

Guillamón CF, Gimeno L, Server G, Martínez-Sánchez MV, Escudero JF, López-Cubillana P, Cabezas-Herrera J, Campillo JA, Abellan DJ, Martínez-García J, Martínez-Escribano J, Ferri B, López-Álvarez MR, Moreno-Alarcón C, Moya-Quiles MR, Muro M, Minguela A. Immunological risk stratification of bladder cancer based on peripheral blood natural killer cell biomarkers. Eur Urol Oncol. 2021;4:246–55.PubMedCrossRef

16.

Xu Y, Zeng H, Jin K, Liu Z, Zhu Y, Xu L, Wang Z, Chang Y, Xu J. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J Immunother Cancer. 2022;10:e003416.PubMedPubMedCentralCrossRef

17.

Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, Konishi N, Toritsuka M, Kishimoto T, Rosser CJ, Fujimoto K. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia. 2016;18:636–46.PubMedPubMedCentralCrossRef

18.

Groeneveld CS, Fontugne J, Cabel L, Bernard-Pierrot I, Radvanyi F, Allory Y, de Reyniès A. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer. 2021;148:181–9.PubMedCrossRef

19.

Lee HW, Chung W, Lee HO, Jeong DE, Jo A, Lim JE, Hong JH, Nam DH, Jeong BC, Park SH, Joo KM, Park WY. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med. 2020;12:47.PubMedPubMedCentralCrossRef

20.

Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, Yin M, Cui C, Wang G, Yuan L, Gao Q, Li Y. JNK Signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA. Cancer Res. 2022;82:1789–802.PubMedCrossRef

21.

Zhang D, Reyes RM, Osta E, Kari S, Gupta HB, Padron AS, Kornepati AVR, Kancharla A, Sun X, Deng Y, Wu B, Vadlamudi R, Li R, Svatek RS, Curiel TJ. Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy. Cancer Med. 2021;10:2137–52.PubMedPubMedCentralCrossRef

22.

Liu Z, Tang Q, Qi T, Othmane B, Yang Z, Chen J, Hu J, Zu X. A robust hypoxia risk score predicts the clinical outcomes and tumor microenvironment immune characters in bladder cancer. Front Immunol. 2021;12:725223.PubMedPubMedCentralCrossRef

23.

McNiel EA, Tsichlis PN. Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. Signal Transduct Target Ther. 2017;2:16045.PubMedPubMedCentralCrossRef

24.

Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. Intratumoral CD4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell. 2020;181:1612-1625.e1613.PubMedPubMedCentralCrossRef

25.

Zhou M, Zhang Z, Bao S, Hou P, Yan C, Su J, Sun J. Computational recognition of lncRNA signature of tumor-infiltrating B lymphocytes with potential implications in prognosis and immunotherapy of bladder cancer. Brief Bioinform. 2021;22:bbaa047.PubMedCrossRef

26.

Liu Q, You B, Meng J, Huang CP, Dong G, Wang R, Chou F, Gao S, Chang C, Yeh S, Xu W. Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling. Cancer Gene Ther. 2022;29:1988–2000.PubMedPubMedCentralCrossRef

27.

Massari F, Ciccarese C, Santoni M, Iacovelli R, Mazzucchelli R, Piva F, Scarpelli M, Berardi R, Tortora G, Lopez-Beltran A, Cheng L, Montironi R. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016;45:46–57.PubMedCrossRef

28.

Cao D, Qi Z, Pang Y, Li H, Xie H, Wu J, Huang Y, Zhu Y, Shen Y, Zhu Y, Dai B, Hu X, Ye D, Wang Z. Retinoic acid-related orphan receptor C regulates proliferation, glycolysis, and chemoresistance via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer. Cancer Res. 2019;79:2604–18.PubMedCrossRef

29.

Pellerin È, Chabaud S, Pouliot F, Pelletier M, Bolduc S. Bisphenol A alters the energy metabolism of stromal cells and could promote bladder cancer progression. Cancers. 2021;13:5461.PubMedPubMedCentralCrossRef

30.

Wigner P, Grębowski R, Bijak M, Saluk-Bijak J, Szemraj J. The interplay between oxidative stress, inflammation and angiogenesis in bladder cancer development. Int J Mol Sci. 2021;22:4483.PubMedPubMedCentralCrossRef

31.

Islam MO, Bacchetti T, Ferretti G. Alterations of antioxidant enzymes and biomarkers of nitro-oxidative stress in tissues of bladder cancer. Oxid Med Cell Longev. 2019;2019:2730896.PubMedPubMedCentralCrossRef

32.

Xie R, Cheng L, Huang M, Huang L, Chen Z, Zhang Q, Li H, Lu J, Wang H, Zhou Q, Huang J, Chen X, Lin T. NAT10 Drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer. Cancer Res. 2023;83:1666–83.PubMedCrossRef

33.

Wu J, Tan Z, Li H, Lin M, Jiang Y, Liang L, Ma Q, Gou J, Ning L, Li X, Guan F. Melatonin reduces proliferation and promotes apoptosis of bladder cancer cells by suppressing o-GlcNAcylation of cyclin-dependent-like kinase 5. J Pineal Res. 2021;71:e12765.PubMedCrossRef

34.

Chen Y, Wang HH, Chang HH, Huang YH, Wang JR, Changchien CY, Wu ST. Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells. Phytomedicine. 2021;87:153587.PubMedCrossRef

35.

Shan G, Zhou X, Gu J, Zhou D, Cheng W, Wu H, Wang Y, Tang T, Wang X. Downregulated exosomal microRNA-148b-3p in cancer associated fibroblasts enhance chemosensitivity of bladder cancer cells by downregulating the Wnt/β-catenin pathway and upregulating PTEN. Cell Oncol. 2021;44:45–59.CrossRef

36.

Xu H, Ju L, Xiong Y, Yu M, Zhou F, Qian K, Wang G, Xiao Y, Wang X. E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability. Cell Death Dis. 2021;12:239.PubMedPubMedCentralCrossRef

37.

Wang X, He H, Rui W, Zhang N, Zhu Y, Xie X. TRIM38 triggers the uniquitination and degradation of glucose transporter type 1 (GLUT1) to restrict tumor progression in bladder cancer. J Transl Med. 2021;19:508.PubMedPubMedCentralCrossRef

38.

Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003;89:1290–7.PubMedPubMedCentralCrossRef

39.

Xu C, Yang X, Wang Y, Ding N, Han R, Sun Y, Wang Y. An analysis of the polymorphisms of the GLUT1 gene in urothelial cell carcinomas of the bladder and its correlation with p53, Ki67 and GLUT1 expressions. Cancer Gene Ther. 2017;24:297–303.PubMedCrossRef

40.

Li M, Che N, Jin Y, Li J, Yang W. CDKN3 Overcomes bladder cancer cisplatin resistance via LDHA-dependent glycolysis reprogramming. Onco Targets Ther. 2022;15:299–311.PubMedPubMedCentralCrossRef

41.

Li T, Tong H, Yin H, Luo Y, Zhu J, Qin Z, Yin S, He W. Starvation induced autophagy promotes the progression of bladder cancer by LDHA mediated metabolic reprogramming. Cancer Cell Int. 2021;21:597.PubMedPubMedCentralCrossRef

42.

Liao AC, Li CF, Shen KH, Chien LH, Huang HY, Wu TF. Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma. Pathology. 2011;43:707–12.PubMedCrossRef

43.

Qiu H, Hu X, He C, Yu B, Li Y, Li J. Identification and validation of an individualized prognostic signature of bladder cancer based on seven immune related genes. Front Genet. 2020;11:12.PubMedPubMedCentralCrossRef

44.

Zhang J, Huang C, Yang R, Wang X, Fang B, Mi J, Yuan H, Mo Z, Sun Y. Identification of immune-related subtypes and construction of a novel prognostic model for bladder urothelial cancer. Biomolecules. 2022;12:1670.PubMedPubMedCentralCrossRef

45.

Cao R, Yuan L, Ma B, Wang G, Tian Y. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA). Cancer Cell Int. 2020;20:276.PubMedPubMedCentralCrossRef

46.

Gao Z, Chen C, Gu P, Chen J, Liu X, Shen J. The tumor microenvironment and prognostic role of autophagy- and immune-related genes in bladder cancer. Cancer Biomark. 2022;35:293–303.PubMedCrossRef

47.

Ding K, Zheng Z, Han Y, Huang X. Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer. Cell Cycle. 2022;21:2533–49.PubMedPubMedCentralCrossRef

48.

Rogers RF, Walton MI, Cherry DL, Collins I, Clarke PA, Garrett MD, Workman P. CHK1 inhibition is synthetically lethal with loss of B-family DNA polymerase function in human lung and colorectal cancer cells. Cancer Res. 2020;80:1735–47.PubMedPubMedCentralCrossRef

49.

Zhang C, Shen Y, Gao L, Wang X, Huang D, Xie X, Xu D, He H. Targeting POLE2 creates a novel vulnerability in renal cell carcinoma via modulating stanniocalcin 1. Front Cell Dev Biol. 2021;9:622344.PubMedPubMedCentralCrossRef

50.

Spier I, Holzapfel S, Altmüller J, Zhao B, Horpaopan S, Vogt S, Chen S, Morak M, Raeder S, Kayser K, Stienen D, Adam R, Nürnberg P, Plotz G, Holinski-Feder E, Lifton RP, Thiele H, Hoffmann P, Steinke V, Aretz S. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. 2015;137:320–31.PubMedCrossRef

51.

Zekri AR, Hassan ZK, Bahnassy AA, Khaled HM, El-Rouby MN, Haggag RM, Abu-Taleb FM. Differentially expressed genes in metastatic advanced Egyptian bladder cancer. Asian Pac J Cancer Prev. 2015;16:3543–9.PubMedCrossRef

52.

Ni L, Sun P, Fan X, Li Z, Ren H, Li J. Berberine inhibits FOXM1 dependent transcriptional regulation of POLE2 and interferes with the survival of lung adenocarcinoma. Front Pharmacol. 2021;12:775514.PubMedCrossRef

53.

Li J, Wang J, Yu J, Zhao Y, Dong Y, Fan Y, Li N, Zhang Y, Wang Y. Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro. Oncol Rep. 2018;40:2477–86.PubMedPubMedCentral

54.

Zhu Y, Chen G, Song Y, Chen Z, Chen X. POLE2 knockdown reduce tumorigenesis in esophageal squamous cells. Cancer Cell Int. 2020;20:388.PubMedPubMedCentralCrossRef

55.

Lee H, Kim K, Woo J, Park J, Kim H, Lee KE, Kim H, Kim Y, Moon KC, Kim JY, Park IA, Shim BB, Moon JH, Han D, Ryu HS. Quantitative proteomic analysis identifies AHNAK (Neuroblast Differentiation-Associated Protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. Mol Cell Proteomics. 2018;17:1788–802.PubMedPubMedCentralCrossRef

56.

Zhang Z, Yu Y, Li P, Wang M, Jiao W, Liang Y, Niu H. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer. Front Immunol. 2022;13:954616.PubMedPubMedCentralCrossRef

57.

Benaud C, Gentil BJ, Assard N, Court M, Garin J, Delphin C, Baudier J. AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture. J Cell Biol. 2004;164:133–44.PubMedPubMedCentralCrossRef

58.

Zheng M, Liu J, Bian T, Liu L, Sun H, Zhou H, Zhao C, Yang Z, Shi J, Liu Y. Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma. Int Immunopharmacol. 2021;90:107134.PubMedCrossRef

59.

Chen B, Wang J, Dai D, Zhou Q, Guo X, Tian Z, Huang X, Yang L, Tang H, Xie X. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer. J Exp Clin Cancer Res. 2017;36:65.PubMedPubMedCentralCrossRef

60.

Kouno M, Kondoh G, Horie K, Komazawa N, Ishii N, Takahashi Y, Takeda J, Hashimoto T. Ahnak/Desmoyokin is dispensable for proliferation, differentiation, and maintenance of integrity in mouse epidermis. J Invest Dermatol. 2004;123:700–7.PubMedCrossRef

61.

Shankar J, Messenberg A, Chan J, Underhill TM, Foster LJ, Nabi IR. Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010;70:3780–90.PubMedCrossRef

62.

Zhang P, Yang Q. Overexpression of SHMT2 predicts a poor prognosis and promotes tumor cell growth in bladder cancer. Front Genet. 2021;12:682856.PubMedPubMedCentralCrossRef

63.

Zhong W, Wang D, Yao B, Chen X, Wang Z, Qu H, Ma B, Ye L, Qiu J. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer. J Zhejiang Univ Sci B. 2021;22:664–81.PubMedPubMedCentralCrossRef

64.

Khalil BD, Sanchez R, Rahman T, Rodriguez-Tirado C, Moritsch S, Martinez AR, Miles B, Farias E, Mezei M, Nobre AR, Singh D, Kale N, Sproll KC, Sosa MS, Aguirre-Ghiso JA. An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med. 2022;219:e2021083.CrossRef

65.

Gui CP, Li JY, Fu LM, Luo CG, Zhang C, Tang YM, Zhang LZ, Shu GN, Wu RP, Luo JH. Identification of mRNA vaccines and conserved ferroptosis related immune landscape for individual precision treatment in bladder cancer. J Big Data. 2022;9:88.PubMedPubMedCentralCrossRef

66.

Sun J, Yue W, You J, Wei X, Huang Y, Ling Z, Hou J. Identification of a novel ferroptosis-related gene prognostic signature in bladder cancer. Front Oncol. 2021;11:730716.PubMedPubMedCentralCrossRef

67.

Su H, Tao T, Yang Z, Kang X, Zhang X, Kang D, Wu S, Li C. Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression. Mol Cancer. 2019;18:27.PubMedPubMedCentralCrossRef

68.

Huang X, Liang H, Zhang H, Tian L, Cong P, Wu T, Zhang Q, Gao X, Li W, Chen A, Zhang Y, Dong Q, Wan H, He M, Dai D, Li Z, Xiong L. The potential mechanism of cancer patients appearing more vulnerable to SARS-CoV-2 and poor outcomes: a pan-cancer bioinformatics analysis. Front Immunol. 2021;12:804387.PubMedCrossRef

69.

Gao L, Ren R, Shen J, Hou J, Ning J, Feng Y, Wang M, Wu L, Sun Y, Wang H, Wang D, Cao J. Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer. BMC Cancer. 2022;22:1016.PubMedPubMedCentralCrossRef

70.

Xu C, Pei D, Liu Y, Yu Y, Guo J, Liu N, Kang Z. Identification of a novel tumor microenvironment prognostic signature for bladder urothelial carcinoma. Front Oncol. 2022;12:818860.PubMedPubMedCentralCrossRef

71.

Liu C, Liu D, Wang F, Liu Y, Xie J, Xie J, Xie Y. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma. Front Immunol. 2022;13:1038927.PubMedPubMedCentralCrossRef

72.

Chen X, Qiu H, Wang C, Yuan Y, Tickner J, Xu J, Zou J. Molecular structure and differential function of choline kinases CHKα and CHKβ in musculoskeletal system and cancer. Cytokine Growth Factor Rev. 2017;33:65–72.PubMedCrossRef

73.

Yang L, Huang W, Bai X, Wang H, Wang X, Xiao H, Li Y. Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling. Cell Death Dis. 2023;14:363.PubMedPubMedCentralCrossRef

74.

Helzlsouer KJ, Comstock GW, Morris JS. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res. 1989;49:6144–8.PubMed

75.

Boorjian S, Tickoo SK, Mongan NP, Yu H, Bok D, Rando RR, Nanus DM, Scherr DS, Gudas LJ. Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer. Clin Cancer Res. 2004;10:3429–37.PubMedCrossRef

76.

Toki K, Enokida H, Kawakami K, Chiyomaru T, Tatarano S, Yoshino H, Uchida Y, Kawahara K, Nishiyama K, Seki N, Nakagawa M. CpG hypermethylation of cellular retinol-binding protein 1 contributes to cell proliferation and migration in bladder cancer. Int J Oncol. 2010;37:1379–88.PubMed

77.

Yang M, Liu X, Tang X, Sun W, Ji Z. LC-MS based urine untargeted metabolomic analyses to identify and subdivide urothelial cancer. Front Oncol. 2023;13:1160965.PubMedPubMedCentralCrossRef

78.

Niu L, Ding L, Lu C, Zuo F, Yao K, Xu S, Li W, Yang D, Xu X. Flavokawain A inhibits cytochrome P450 in in vitro metabolic and inhibitory investigations. J Ethnopharmacol. 2016;191:350–9.PubMedCrossRef

79.

Kuwada H, Ihara K, Imaishi H. Development of a new assay system for bladder cancer using interactions between cytochromes P450 and serum. Drug Metab Pharmacokinet. 2022;47:100472.PubMedCrossRef

80.

Zhang Y, Chen Q, Gong M, Zeng Y, Gao D. Gene regulatory networks analysis of muscle-invasive bladder cancer subtypes using differential graphical model. BMC Genomics. 2021;22:863.PubMedPubMedCentralCrossRef

81.

Kong DB, Chen F, Sima N. Focal adhesion kinases crucially regulate TGFβ-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin. Onco Targets Ther. 2017;10:1783–92.PubMedPubMedCentralCrossRef

82.

Kong D, Chen F, Sima NI. Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway. Exp Ther Med. 2015;10:1725–31.PubMedPubMedCentralCrossRef

83.

Zhao F, Yang T, Zhou L, Li R, Liu J, Zhao J, Jia R. Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combing β-integrin. Aging. 2023;15:4182–201.PubMedPubMedCentralCrossRef

Title: BLCA prognostic model creation and validation based on immune gene-metabolic gene combination
Authors: Shao-Yu Yue
Di Niu
Xian-Hong Liu
Wei-Yi Li
Ke Ding
Hong-Ye Fang
Xin-Dong Wu
Chun Li
Yu Guan
He-Xi Du
Publication date: 01-12-2023
Publisher: Springer US
Keyword: Biomarkers
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00853-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

The role of pyroptosis-related lncRNA risk signature in ovarian cancer prognosis and immune system

Adipocyte-derived extracellular vesicles: bridging the communications between obesity and tumor microenvironment

Myc derived circRNA promotes triple-negative breast cancer progression via reprogramming fatty acid metabolism

A comprehensive analysis of SLC25A1 expression and its oncogenic role in pan-cancer

CT-measured body composition radiomics predict lymph node metastasis in localized pancreatic ductal adenocarcinoma

M6A-mediated upregulation of HOXC10 promotes human hepatocellular carcinoma development through PTEN/AKT/mTOR signaling pathway

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials